Zimmer Biomet Holdings (STU:ZIM) 3-Year Revenue Growth Rate : 6.00% (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Zimmer Biomet Holdings 3-Year Revenue Growth Rate?

Zimmer Biomet Holdings's Revenue per Share for the three months ended in Sep. 2024 was €8.10.

During the past 12 months, Zimmer Biomet Holdings's average Revenue per Share Growth Rate was 6.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -2.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was 1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Zimmer Biomet Holdings was 25.60% per year. The lowest was -8.20% per year. And the median was 9.30% per year.

Competitive Comparison of Zimmer Biomet Holdings's 3-Year Revenue Growth Rate

For the Medical Devices subindustry, Zimmer Biomet Holdings's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zimmer Biomet Holdings's 3-Year Revenue Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's 3-Year Revenue Growth Rate falls into.

Zimmer Biomet Holdings 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Zimmer Biomet Holdings (STU:ZIM) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Zimmer Biomet Holdings 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (STU:ZIM) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

ZBH:USA ZBH:Mexico ZIM:Germany ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.